Biocept, Inc. (BIOC) News

Biocept, Inc. (BIOC): $1.07

0.02 (+2.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter BIOC News Items

BIOC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BIOC News Highlights

  • BIOC's 30 day story count now stands at 5.
  • Over the past 12 days, the trend for BIOC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest BIOC News From Around the Web

Below are the latest news stories about Biocept Inc that investors may wish to consider to help them evaluate BIOC as an investment opportunity.

Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer

SAN DIEGO, February 22, 2022--Biocept highlights CNSide assay's ability to aid clinical research efforts to improve treatment of metastatic cancers involving brain.

Yahoo | February 22, 2022

Biocept, Inc. (NASDAQ:BIOC) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Biocept (NASDAQ:BIOC) has had a rough three months with its share price down 28%. However, the company's fundamentals...

Yahoo | February 18, 2022

Biocept appoints Samuel Riccitelli as interim president, CEO

Biocept (BIOC) appointed Samuel Riccitelli as interim president and CEO, succeeding Michael Nall.Riccitelli, who will remain chair of the board, recently served as CEO of Pathnostics,…

Seeking Alpha | February 16, 2022

Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer

SAN DIEGO, February 16, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W. Nall, and Antonino Morales as Interim Chief Financial Officer, succeeding Timothy C. Kennedy. Biocept also named M. Faye Wilson as Lead Independent Director of the company’s Board of Directors. Mr. Riccitelli remains Chair of the Board.

Yahoo | February 16, 2022

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

SAN DIEGO, February 10, 2022--Biocept names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer.

Yahoo | February 10, 2022

Biocept reports increase in COVID-19 RT-PCR testing due to Omicron

Biocept (BIOC) said the COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.The company has received more than 40K samples for COVID-19…

Seeking Alpha | January 21, 2022

Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant

SAN DIEGO, January 21, 2022--Biocept has received more than 765,000 samples for RT-PCR COVID-19 testing since June 2020.

Yahoo | January 21, 2022

Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?

Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.

Yahoo | January 7, 2022

Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10

SAN DIEGO, January 04, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the Biocept presentation can be accessed on the Investor Relations section of the company website beginning on January 10, 2022 at 7:00 a.m. Eastern time.

Yahoo | January 4, 2022

Biocept (NASDAQ:BIOC) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a research note issued to investors on Monday morning, Zacks.com reports. The brokerage currently has $4.25 price objective on the medical research companys stock. According to Zacks, Biocept, Inc. is a commercial stage oncology diagnostics company. It has []

Transcript Daily | December 24, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.9959 seconds.